Abatacept: Clinical trial started

The U.K.’s National Institute for Health Research began the placebo-controlled, European APIPPRA clinical trial to evaluate 125 mg subcutaneous abatacept weekly for 1 year in 206 patients who have joint pains and evidence of an autoimmune response in their blood, but no joint swelling. Bristol-Myers is providing the product and a L3 million ($4.5 million) grant for the trial. ...